Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab Maintenance in CLL/SLL
NCT01258933Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2011
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ofatumumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2011; status: terminated.
02
Drugs
ofatumumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01258933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01258933.